Medical Condition News

RSS

Trabedersen granted orphan drug designation from both FDA And EMEA for treating pancreatic carcinoma

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma.

14 Sep 2009

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced data presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the potential of TYSABRI® (natalizumab) to redefine successful multiple sclerosis (MS) therapy.

14 Sep 2009

Special Projects Discovery Grant program launched for brain tumor diagnosis research

The American Brain Tumor Association has launched a new Special Projects Discovery Grant program to support fresh and creative research ideas for solving the challenges of brain tumor diagnosis and treatment.

14 Sep 2009

Results further support the benefits of TYSABRI for multiple sclerosis patients

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI- (natalizumab) experienced an improvement in both their physical function and psychological well-being.

14 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009

Master gene could lead to new ways of cancer treatments

The master gene that causes blood stem cells to turn into disease-fighting 'Natural Killer' (NK) immune cells has been identified by scientists, in a study published in Nature Immunology today. The discovery could one day help scientists boost the body's production of these frontline tumour-killing cells, creating new ways to treat cancer.

14 Sep 2009

New method for detecting oxidative stress in tumor cells

The growth of cancerous tumors is fueled, at least in part, by the buildup of free radicals---highly reactive oxygen-containing molecules.

14 Sep 2009

DaVita Kidney Awareness Run/Walks increases CKD awareness

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), kicks off the DaVita Kidney Awareness Run/Walks(TM) - a 10-city series of 5K events raising funds and awareness of CKD across the nation -- on Sept. 13 at Stapleton Central Park in Denver.

14 Sep 2009

Depression increases disease progression and mortality in cancer patients

Depression can affect a cancer patient's likelihood of survival. That is the finding of an analysis published in the November 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society. The results highlight the need for systematic screening of psychological distress and subsequent treatments.

14 Sep 2009

Lack of awareness affects surgery referrals

Overblown fears about surgical risk and lack of awareness about the risk of not operating are among the reasons only half of eligible patients were referred for mitral valve repair, according to a study by doctors at the University of Michigan Cardiovascular Center.

14 Sep 2009

Scientific program to treat and prevent mental disorders

Mental disorders are a global problem and represent one of the biggest challenges for health care systems. In the world, there are some 500 million people suffering from mental disorders, and in the European Union, mental disorders range as one of the leading causes of disease burden.

14 Sep 2009

Scientists to get funding from The European Research Council

The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007.

11 Sep 2009

OCC partners with Consuelo Vanderbilt Costin to raise public awareness about ovarian cancer

The Ovarian Cancer Coalition of Greater California (OCC) has partnered with singer/songwriter/actress/philanthropist Consuelo Vanderbilt Costin for Ovarian Cancer Awareness Month, by launching a public women's health campaign for the fight against ovarian cancer.

11 Sep 2009

End stage renal disease can be delayed by early identification of CKD

Early identification of individuals with chronic kidney disease (CKD) can delay the onset of end stage renal disease (ESRD) and the need for chronic dialysis treatments. The incidence of CKD continues to grow, and early identification and intervention are critical to manage this costly disease.

11 Sep 2009

Children with larger waists are more at risk of developing cardiovascular disease later in life

Children with more fat around their midsections could be at a higher risk of developing cardiovascular disease later in life, researchers say.

11 Sep 2009

Weight training may help the elderly retain muscle

Have you ever noticed that people have thinner arms and legs as they get older? As we age it becomes harder to keep our muscles healthy. They get smaller, which decreases strength and increases the likelihood of falls and fractures. New research is showing how this happens — and what to do about it.

11 Sep 2009

Accupac to manufacture Access Pharmaceuticals' MuGard

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

11 Sep 2009

Mayo study raises hope for treating multiple sclerosis

A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS). These findings give researchers new hope for developing more effective therapies for patients with MS and for predicting MS patients' outcomes. This study will be presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Dusseldorf, Germany, on Sept. 11, 2009.

11 Sep 2009

Genspera to commence G-202 Phase I trial following FDA approval

GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer.

11 Sep 2009

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that two companion articles highlighting results from the BRITE-MD (Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major Depression) were published in the September issue of the journal Psychiatry Research.

11 Sep 2009